Does the fibromyalgia affect the quality of life in the patients with inflammatory bowel disease

Abstract

Background and aims: Data on the soft tissue rheumatism, especially fibromyalgia syndrome is limited in inflammatory bowel disease. Our aim in our study is to determine the prevalence of fibromyalgia syndrome and to evaluate the impact of it on quality of life in inflammatory bowel disease. Methods: 60 ulcerative colitis and 34 Crohn's disease patients were included. 2010/2011 and 2016 American College of Rheumatology criteria were used for fibromyalgia syndrome diagnosis. Fibromyalgia impact survey was applied to the all patients. Results: According to the American Colloge of Rheumatology-2010/2011 criteria, fibromyalgia syndrome frequencies were determined as 29.8% in inflammatory bowel disease, 23.4% in Crohn’s disease and 33.3% in ulcerative colitis (P ˃ 0.05). The frequency of fibromyalgia syndrome was significantly higher in inflammatory bowel disease and especially more in female. There was no significant difference between ulcerative colitis and Crohn’s disease in terms of widespread-pain-index, somatic-symptom-severity and fibromyalgia syndrome scores. Fibromyalgia impact scores were found significantly higher in those with fibromyalgia syndrome in inflammatory bowel disease, ulcerative colitis and Crohn’s disease. Conclusions: This is the first study to show the frequency of fibromyalgia syndrome in patients with inflammatory bowel disease in Turkish population. Fibromyalgia syndrome has been shown to be increased in inflammatory bowel disease patients and more in ulcerative colitis and female. The quality of life is more affected in inflammatory bowel disease patients with fibromyalgia syndrome.

Keywords

• Crohn’s Disease
• Fibromyalgia Syndrome
• Inflammatory Bowel Disease
• Ulcerative Colitis

References

1. 1. Ott C, Schölmerich J. Extraintestinal manifestations ve complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10:585-95.
2. 2. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 2011;4:123-31.
3. 3. Peluso R, Di Minno MND, Lervolino S, Manguso F, Tramontano G, Ambrosino P, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013;2013:631408.
4. 4. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J Rheumatol 1999;26:1167-71.
5. 5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for The Classification of Fibromyalgia. Report of yhe Multicenter Criteria Commitee. Arthiritis Rheum 1990;33:160-72.
6. 6. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2596 people with fibromyalgia. BMC Musculoskeletal Disorders 2007;8:27.
7. 7. Wolfe F, Ross K, Anderson J, Russel IJ. Aspects of fibromyalgia in the general population: sex, pain threshold and fibromyalgia symptoms. J Rheumatol 1995;22:151-6.
8. 8. Bradley LA. Pathophysiology of fibromyalgia. Am J Med 2009;122:22-30.

9. 9. Calıs M, Gökce C, Ates F, Ülker S, İzgi HB, Demir H, et al. Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1µg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004;27:42-6.
10. 10. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994;37:1583-92.
11. 11. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007;36:339-56.
12. 12. Hauser W, Thieme K, Turk DC. Guidelines on the manegement of fibromyalgia syndrome- a systematic review. Eur J Pain 2010;14:5-10.
13. 13. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. Journal of Rheumatology 1991;18:728-34.
14. 14. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American Collage of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research 2010;62:600-10.
15. 15. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319-29.
16. 16. Topbaş M, Çakırbay H, Güleç H, Akgol E, Ak I, Can G. The prevalance of fibromyalgia in women aged in Turkey. Scand J Rheumatol 2005;34:140-4.
17. 17. Clauw DJ. Fibromyalgia: An overwiew. Am J Med 2009;122:S3-13.
18. 18. Palm O, Moum B, Jahnsen J, Gran JT. Fibromyalgia and chronic widespread pain in a population in patients with inflammatory bowel disease: a cross sectional population survey. J Rheumatol 2001;28:590-4.
19. 19. D'Incà R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 2009;41:565-9.
20. 20. Fatemi A, Jazi HH, Emami MH, Kazemizadeh A, Tavakkoli H, Smiley A. Relationship between articular and nonarticular manifestations in inflammatory bowel diseases. J Res Med Sci 2016;14:48.
21. 21. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113-22.
22. 22. Ablin JN, Wolfe F. A comparative evaluation of the 2011 and 2016 criteria for fibromyalgia. J Rheumatol 2017;44:1271-6.
23. 23. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33.
24. 24. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the fibromyalgia impact questionnaire. Rheumatol Int 2000;20:9-12.